Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans - WAVE Life Sciences ( NASDAQ:WVE )
Wave Life Sciences Ltd. WVE stock is trading higher on Wednesday after the company revealed proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency ( AATD ) , an inherited genetic disorder that causes low levels of a protein ( AAT ) ...
| Ticker |
Sentiment |
Impact |
|
GSK
|
Neutral
|
31 %
|
|
WVE
|
Somewhat Bullish
|
66 %
|
